相关实验视频

Updated: Jul 19, 2026

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Published on: January 4, 2019

富血小板血与皮质类固醇注射在患有初级冷肩的患者:一个单盲随机对照试验

Lin-Fen Hsieh¹, Yu-Shan Fu², Ting-An Chen²

¹Department of Physical Medicine and Rehabilitation, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.

Archives of physical medicine and rehabilitation

|February 28, 2026

概括

与血小板丰富的血或盐水注射相比,与物理治疗相结合的皮质类固醇注射显著改善了冷肩部的结果. 所有治疗都显示出改善,但皮质类固醇更优越,特别是在早期冷阶段.

科学领域:

整形外科整形外科整形外科
再生医学是一种再生医学.
肌肉骨康复肌肉骨康复

背景情况:

结的肩膀 (粘性囊炎) 是一种使人虚弱的疾病,其特点是疼痛和运动范围受到限制.
目前的治疗选择包括物理治疗,皮质类固醇注射和新兴的再生疗法,如富血小板血.

研究的目的:

为了比较结合腺关节 (GHJ) 和亚-亚骨突 (SASD) 突注射丰富血小板血 (PRP),皮质类固醇 (CSs) 或正常盐水 (NS),以及物理治疗 (PT) 的疗效,用于治疗结的肩膀.

主要方法:

进行了一项前性,单盲,随机对照试验,对90名被诊断患有初级结肩膀的患者进行了随机对照试验.
参与者被随机分为三个组:PRP + PT,CS + PT,或NS + NS + PT.
超声波导向注射针对GHJ和SASD bursa,在基线和治疗后1,2,4和6个月评估结果.

主要成果:

与PRP和NS组相比,皮质类固醇 (CS) 组在肩膀疼痛和残疾指数 (SPADI),肩膀残疾问卷 (SDQ),疼痛视觉模拟尺度 (VAS),主动和被动运动范围,患者自我评估和SF-36分数方面表现出统计学上显著的改善.
这些好处早在1个月就被观察到,并在6个月的随访期内持续存在.

结论:

皮质类固醇注射,结合物理治疗,比PRP或NS注射更有效治疗结的肩膀,特别是在最初的结阶段.
虽然CSs显示出优异的结果,但所有研究的治疗方式都导致了患者结果的显著改善.

关键词:

在PRP中,PRP是指PRP.粘合性囊炎是一种粘合性囊炎.这是一种皮质类固醇.结的肩膀结的肩膀富有血小板血的血.

更多相关视频

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy

Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy

Published on: November 17, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...